SCHEMBL30817551

SCHEMBL30817551

CCCC(=O)NNC(=S)NC1(C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.54
KMT2A Q03164 5/20 0.54
MEN1 O00255 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
KDM4E B2RXH2 6/20 0.44
ALDH1A1 P00352 8/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
PKM P14618 1/20 0.42
LMNA P02545 3/20 0.38
POLB P06746 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
GAA P10253 1/20 0.37
CTSD P07339 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17033150 0.81 HDAC3 (0.46) MAPTKMT2AMEN1NPSR1ALDH1A1
SCHEMBL17033159 0.73 EPHX2 (0.47) MAPTKMT2AMEN1NPSR1KDM4E
SCHEMBL6634673 0.73 HDAC3 (0.63) MAPTKMT2AMEN1NPSR1KDM4E
SCHEMBL24974708 0.72 LMNA (0.49) MAPTKDM4EALDH1A1SMN1; SMN2LMNA
SCHEMBL8689464 0.72 LMNA (0.49) MAPTKDM4EALDH1A1SMN1; SMN2LMNA
SCHEMBL29092803 0.69 MAPT (0.73) MAPTKMT2AMEN1NPSR1KDM4E
SCHEMBL8515420 0.69 MAPT (0.55) MAPTKMT2AMEN1NPSR1KDM4E
SCHEMBL828036 0.68
SCHEMBL29034238 0.67 MAPT (0.69) MAPTKMT2AMEN1NPSR1KDM4E
SCHEMBL10044121 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568948-A1 COMPOUNDS FOR TREATING CANCER Genesis Therapeutics, Inc. (US) 2025-06-18 EP disclosed
WO-2024059010-A1 COMPOUNDS FOR TREATING CANCER GENESIS THERAPEUTICS, INC. (US) 2024-03-21 WO disclosed